Heterogeneity and subtypes of CD4+ regulatory T cells: implications for tumor therapy

Front Immunol. 2024 Jan 5:14:1291796. doi: 10.3389/fimmu.2023.1291796. eCollection 2023.

Abstract

In the conventional view, CD4+ regulatory T cell (Treg) represents a subset of lymphocytes that involve the perception and negative regulation of the immune response. CD4+Treg plays an important role in the maintenance of immune homeostasis and immune tolerance. However, recent studies have revealed that CD4+Treg do not suppress the immune response in some diseases, but promote inflammatory injury or inhibit tissue remodeling, suggesting the functional heterogeneity of CD4+Treg. Their involvement in tumor pathogenesis is more complex than previously understood. This article reviews the relevant research on the heterogeneity of CD4+Treg, subtype classification, and their relationship with tumor therapy.

Keywords: clinical trials; forkhead box protein 3; functional subtypes; regulatory T cells; tumor microenvironment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Homeostasis
  • Immune Tolerance*
  • T-Lymphocytes, Regulatory*

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by grants from the National Natural Science Foundation of China (82271143 to YX), and the Startup Fund for Talents of Fujian Province (YJRC4120 to HL).